A realistic expectation of energy changes, combined with proactive monitoring, significantly improves treatment adherence and outcomes
Our team reviews your health history, medications, and relevant conditions before treatment to help ensure safety
The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function
Experimental evidence has demonstrated that a decrease in ascorbic acid levels is tied to GSH depletion [12]
What little evidence is available suggests it may be beneficial in tissue-healing processes, which is why athletes may turn to it for muscle recovery purposes (11, 12)
Semaglutide was originally approved in 2017 by the U.S